Recent stability results detected particulate matter in clinical batches of the intravenous formulation of Fodosine. Preliminary findings have suggested that the particulates are associated with the vial stoppers
The first fast track designation is for the use of rNAPc2 as a first-line treatment to improve progression-free survival and overall survival when added to Avastin-containing 5- flurourocil
The trial showed a significant increase in the proportion of patients who remained relapse-free over the first 12 months of treatment with 60mg per day of the treatment,
Intrinsa is the first treatment for women with low sex drives and has been branded a female Viagra. Intrinsa is a clear patch worn on the abdomen that
The drug known as CRx-139 is a synergistic combination of 3mg prednisolone and the antidepressant paroxetine. CRx-139 did show statistical significance on multiple other endpoints which require further
Although rare, diffuse large B-cell lymphoma (DLBCL) is the most common sub-type of non-Hodgkin's lymphoma (NHL). Enrolment into a phase III trial studying enzastaurin is currently underway. The
BeneFix is a coagulation factor created using recombinant DNA technology to replace clotting factor IX to stop or prevent bleeding in people with hemophilia B who do not
The agreement could help the companies gain a share of the large worldwide market for cholesterol-management treatments which is currently estimated at $32 billion by IMS Health. The
Januvia is now the first medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which enhance the body’s own ability to lower blood
The development of this drug was originally terminated by Pfizer after a separate clinical trial reported that it increased the risk of death and other adverse cardiovascular outcomes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.